Journal
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 20, Issue 6, Pages 357-368Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.euroneuro.2010.02.008
Keywords
GSK3 beta; Review; Gene; Genetics; Bipolar disorder
Ask authors/readers for more resources
We aimed to get a comprehensive insight into the genetic evidence supporting the role of GSK3 beta, in bipolar disorder (BD). Using broad searches in NCBI's PubMed and the Genetic Association Database we looked for association, whole-genome linkage, genome-wide association, gene expression, pharmocogenomic, epigenetic, cytogenetic, and mouse model studies performed for BD until July 2009. Per gene, we rated the degree of converging evidence across these types of genetic studies. The genes most consistently associated with BD in the genetic studies we reviewed were GSK3 beta, GRK3, 5-HTTLPR, GRIN3, COMT, and GLUR3. GSK3 beta stood out as it was implicated in at least five types of genetic studies. Although our results are limited by design differences of Included studies and possibly by publication bias, GSK3 beta is a plausible candidate gene for BD from a pharmacological and a genetic perspective. Future studies investigating the effects of GSK3 beta manipulation in BD seem warranted. (C) 2010 Elsevier B V. and ECNP. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available